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1. Introduction 
Cholinergic neurotransmission plays an essential role in a variety of physiological processes 
in both the central and peripheral nervous systems. Cholinergic neurons use the classical 
neurotransmitter acetylcholine (ACh) to communicate with their target cells. In the 
periphery, ACh is the neurotransmitter used at the skeletal neuromuscular junction, at all 
pre- and postganglionic parasympathetic synapses and at preganglionic sympathetic 
synapses. In the central nervous system, the actions of ACh are widespread with cholinergic 
neurotransmission involved in attention, learning and memory, cognition, sleep, 
wakefulness, and modulation of sensory information (Hasselmo, 2006; Sarter & Parihk, 
2005; Woolf & Butcher, 2010). Dysfunction of cholinergic neurotransmission in the central 
nervous system is apparent in a number of neurological disorders, such as Alzheimer’s, 
Parkinson’s, and Huntington’s diseases, schizophrenia and amyotrophic lateral sclerosis 
(Bohnen & Albin, 2010; Mesulam, 2004; Oda, 1999).  
Cholinergic neurons innervate almost all areas of the brain, where this can be mediated by 
either intrinsic interneurons or by extrinsic projection neurons. Cholinergic interneurons 
localized in the striatum are involved in motor function, cognition, and behavior (Woolf & 
Butcher, 2010). The basal forebrain, which is comprised of the nucleus basalis of Meynert, 
medial septum, diagonal band of Broca, the magnocellular preoptic nucleus, and substantia 
innominata, contains the cell bodies of cholinergic neurons that project to the hippocampus, 
amygdala, olfactory bulb, and all areas of the cerebral cortex (Woolf & Butcher, 2010). 
Collectively, basal forebrain cholinergic neuron activity plays a role in attention, learning, 
memory, perception, and consciousness (Sarter et al., 2003; Woolf, 1998; Woolf & Butcher, 
2010). Cholinergic neurons in the mesopontine region (the pedunculopontine and laterodorsal 
nuclei) project to the thalamus, hypothalamus, basal forebrain, medial frontal cortex, 
brainstem and spinal cord (Woolf & Butcher, 2010). Descending cholinergic projections from 
the mesopontine area decrease muscle tone during rapid eye movement sleep while ascending 
cholinergic projections are involved in cognitive functions and consciousness (Woolf & 
Butcher, 2010). Cholinergic projections to the interpeduncular nucleus originate from neurons 
with cell bodies in the medial habenula; these neurons regulate electroencephalogram patterns 
and rapid eye movement sleep (Woolf & Butcher, 2010).  
The cycle of ACh synthesis, storage, release and degradation has been well-characterized at 
the cellular and molecular levels and is depicted in Figure 1. ACh is synthesized in the 
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cytoplasm of cholinergic neurons from the precursors choline and acetylCoenzyme-A by the 
enzyme choline acetyltransferase (ChAT), and it is then taken up into synaptic vesicles for 
storage by the vesicular acetylcholine transporter (VAChT) (Prado et al., 2002). 
Depolarization of the nerve terminal causes exocytotic fusion of synaptic vesicles with the 
presynaptic membrane at specialized release sites called active zones (Garner et al., 2000); 
this is a calcium-dependent process that involves the coordinated actions of many 
presynaptic proteins such as SNARE and Rab proteins (Sudhof, 2008). When vesicles fuse 
with the presynaptic membrane, ACh diffuses into the synaptic cleft where it can bind to 
nicotinic and muscarinic receptors located on both pre- and postsynaptic cells (Gotti et al., 
2009; Nathanson, 2008). ACh signalling is terminated by its diffusion away from the 
synaptic cleft and by its rapid hydrolysis into choline and acetate by acetylcholinesterase 
(AChE) (Lane et al., 2006). After fusion, synaptic vesicles recycle (S.M. Smith et al., 2008) and 
are re-filled with neurotransmitter in preparation for another round of depolarization-
induced release. The choline derived from ACh hydrolysis is recycled into the presynaptic 
terminal by the sodium-dependent, high-affinity choline transporter CHT for re-synthesis of 
ACh (Birks & MacIntosh, 1961; Collier & MacIntosh, 1969; Collier & Katz, 1974; Haga, 1971; 
Okuda et al., 2000; Yamamura & Snyder, 1972). Mechanistic details of the molecular 
regulation of these processes in both health and disease are lacking. 
 
 
Fig. 1. Mechanisms involved in the synthesis, storage, release and degradation of ACh at the 
cholinergic synapse. Abbreviations: Acetyl Co-A, acetylCoenzyme-A; ACh, acetylcholine; 
AChE, acetylcholinesterase; ChAT, choline acetyltransferase; CHT, sodium-dependent, 
high-affinity choline transporter; M, muscarinic receptor; N, nicotinic receptor; SV, synaptic 
vesicle; VAChT, vesicular ACh transporter. 
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Age-related changes in brain that lead to neuronal and vascular pathology frequently 
compromise synaptic transmission. Many reports associate neurological and cardiovascular 
diseases with cholinergic neuron dysfunction, and draw parallels between the reduction in 
cholinergic neurotransmission and cognitive deficits. However, little is known about the 
actual mechanisms by which these changes impact cholinergic neuron function or the extent 
to which this can be prevented or reversed. Some of these changes are initiated by oxidative 
and nitrosative stress which then increases as the pathology progresses. There is also a 
relationship with altered amyloid precursor protein (APP) metabolism and -amyloid 
peptide (A) production that is likely due to changes in the expression or activity of 
enzymes directing APP into an amyloidogenic pathway. Modified APP/A metabolism is a 
hallmark of Alzheimer’s disease, but is also a result of cardiovascular disease including 
ischemia (Bennett et al., 2000; Lee et al., 2006; Nihashi et al., 2001; Shi et al., 2000), stroke 
(Petcu et al., 2008) and hypertension (Gentile et al., 2009; Skoog et al., 1996; Skoog et al., 
2006). Age-related increases in soluble oligomeric A acutely modulate synaptic 
communication at concentrations far below those causing neurodegeneration, and play a 
central role in Alzheimer’s-related synaptic changes (Marcello et al., 2008). The tissue stress 
response and the generation of reactive oxygen (ROS) and nitrogen species (RNS) in aging 
brain and early stages of vascular and neuronal disease are attributed partly to increasing 
A (De Felice et al., 2007). Increased ROS-RNS can initiate changes that result in both 
reversible and irreversible alterations in protein structure and function. This Chapter 
focuses on studies of ChAT and CHT structure and function in conditions with altered 
exposure to ROS-RNS, and the consequences for cholinergic neuron communication related 
to Alzheimer’s disease pathology and potential outcomes related to neuroprotection. 
2. Cholinergic neuron function in aging brain 
A large literature addresses the role of cholinergic neurons in cognition and attentional 
processes, and their involvement in Alzheimer’s disease (Sarter & Bruno, 1997; Sarter & Bruno, 
2004; Schliebs & Arendt, 2006). The current opinion is that while dysfunction of cholinergic 
neurons is not the cause of this disease, loss of their function is central to changes that occur in 
brain with normal aging and in a spectrum of disorders that includes mild cognitive 
impairment (MCI) (Mesulam, 2004). Studies in aging humans and animal models show that 
some cholinergic pathways have diminished function compared to younger groups. Cognitive 
decline correlates with elevated oxidative stress in a cohort of normal aging human subjects 
(Foster, 2006). Also, in aging rats, spatial learning deficits are associated with elevated markers 
of oxidative stress (Nicolle et al., 2001). However, the small loss of forebrain cholinergic 
neurons does not relate strongly to cognitive status (McKinney & Jacksonville, 2005) providing 
compelling evidence that other dynamic cholinergic processes must be affected that are not 
detected simply by counting the number of neurons. 
A comparison of two cholinergic pathways in aged rat brain suggests that neurons in 
different brain areas can respond differentially to age-related stressors. Basal forebrain 
cholinergic neurons lose the activity or expression of essential proteins that maintain 
chemical transmission and their numbers are reduced, whereas brainstem cholinergic 
neurons in the pontine nuclei are preserved (Baskerville et al., 2006). This is reinforced by 
the observation that cultured pontine neurons are resistant to ROS-RNS whereas basal 
forebrain cholinergic neurons are vulnerable (Fass et al., 2000; McKinney et al., 2004). The 
reasons for this are not known, but age-related oxidative stress in the cortex (Nicolle et al., 
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2001) may elevate basal forebrain neuron metabolism. Oxidatively-stressed aged cortex is 
less responsive to ACh and may compensate for this by requiring enhanced input from 
basal forebrain neurons thereby causing increased neuron firing rates and/or changes such 
as increased expression of genes that are involved in energy production (Baskerville et al., 
2008; Ongwijitwat et al., 2006; Yang et al., 2006). Alternatively, up-regulation of expression 
of metabolic genes may be normal and an “adaptive” consequence of aging in basal 
forebrain neurons that precedes their degeneration (Baskerville et al., 2008). Elevated 
metabolic activity may also precede increased ROS-RNS levels and, along with pathology 
such as increased A levels, may mediate their selective vulnerability. It is important to note 
that basal forebrain cholinergic neurons project to regions with A deposits, whereas 
pontine cholinergic neurons do not.  
A shift in thinking about the timing and nature of changes in cholinergic neuron function in 
aging and disease came about with reports that ChAT activity is unchanged or even 
increased in the hippocampus and cortex of subjects with MCI (DeKosky et al., 2002; 
Ikonomovic et al., 2003; Mufson et al., 2003). This is in sharp contrast to reports of large 
decreases in cholinergic neuron markers and numbers in Alzheimer’s disease (Davies, 1979; 
Francis et al., 1985; Perry et al., 1977; Rylett et al., 1982; Sims et al., 1983). Mechanisms 
underlying this apparent increase in cholinergic neuron function are unknown, but it was 
suggested that basal forebrain cholinergic neurons undergo sprouting in an attempt to 
maintain neurotransmission or to repair entorhinal cortex damage (Ikonomovic et al., 2003). 
This has stimulated studies on the functional status of cholinergic neurons in MCI and early 
Alzheimer’s disease; a pivotal study used pharmacological-functional magnetic resonance 
imaging (fMRI) to document that cholinergic neurotransmission is compromised (Goekoop 
et al., 2006). It is important to note that most of the studies reported to date have monitored 
postsynaptic events for insight into the status of cholinergic neurotransmission and to reveal 
alterations that would result in decreased cholinergic synaptic function and neuron 
responsiveness in MCI and Alzheimer’s disease (Grön et al., 2006). There is a large gap in 
knowledge about the effects that perturbations such as ROS-RNS, A or altered antioxidant 
defense mechanisms have on cholinergic presynaptic functions, and the role that this has in 
compromised neurotransmission. Moreover, most studies have assayed static measures 
such as neuron numbers or enzyme levels that do not accurately reflect the more dynamic 
aspects of neurotransmission (Mesulam, 2004), and this may give an incorrect assessment as 
they do not reveal changes in the capacity for neurotransmitter synthesis and release. 
3. Cholinergic neurons have a role in regulation of APP metabolism  
A critical link has emerged between cholinergic neurons and APP processing. These 
neurons are particularly susceptible to the adverse effects of A, and this may partially 
underlie their vulnerability in amyloidogenic diseases (Auld et al., 1998; Tran el al., 2002). Of 
note however, cholinergic neurons are also integral in the development of amyloid-based 
pathology (Auld et al., 1998; Francis et al., 1999; Tran et al., 2002) as they can regulate APP 
processing and, in turn, A can decrease ACh synthesis and release (Heinitz et al., 2006; 
Hoshi et al., 1996, 1997; Kar et al., 1996, 1998; Pederson et al., 1996; Pederson & Blusztajn, 
1997; Satoh et al., 2001). The stimulation of either nicotinic or muscarinic ACh receptors on 
cholinoreceptive neurons can promote non-amyloidogenic APP cleavage, thereby 
potentially decreasing the production of toxic A (Isacson et al., 2002; Seo et al., 2001; Tran et 
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al., 2002; Unger et al., 2005; Verhoeff, 2005). Thus, the activation of either 7- or 42-
nicotinic receptors (Lahiri et al., 2002; Shimohama & Kihara, 2001; Zamani & Allen, 2001) 
can decrease A toxicity by protecting neurons through activation of PI3-kinase and 
increasing levels of Bcl-2 and Bcl-x50. Taken together, the loss of cholinergic neuron 
innervation may promote A-based pathology, and therapies that would enable cholinergic 
neurotransmission may indirectly decrease neurodegeneration by reducing A production. 
A can assume various physical conformations that may differ in their biological actions. 
These various A peptides are produced both intracellularly and extracellularly and appear 
in brain tissue as soluble oligomers and diffusible ligands (Gong et al., 2003; Klein, 2002; 
Klein et al., 2004) that can aggregate to form insoluble plaques (Kuo et al., 1996; Lue et al., 
1999; Walsh et al., 2002a, 2002b; J. Wang et al., 1999). The increased levels of soluble A 
correlate with synaptic loss and cognitive impairment, and it is now known that synaptic 
neurotransmission is impacted directly by soluble A with this leading to decreased 
memory (Klein, 2002). A can bind to a number of different cell surface receptors, modulate 
synaptic events, lead to generation of ROS-RNS or the release of inflammatory mediators, 
and disrupt cellular calcium homeostasis (W.W. Smith et al., 2006; Tran et al., 2002). In 
animal models having chronic delivery of A into rat brain there is increased iNOS 
expression and disruption of hippocampal cholinergic transmission and memory 
impairment (Tran et al., 2001). 
4. A promotes oxidative stress that can affect neuron function  
The inside of cells is normally a reducing environment that maintains proteins in their 
native reduced states. However, even under these “reducing” conditions some proteins 
do exist in their S-glutathionylated forms (Klatt & Lamas, 2000). Moreover, if ROS-RNS 
generation exceeds the antioxidant capacity of the cell, then oxidative-nitrosative stress 
can occur with modification of cellular constituents causing loss of their function. A, 
particularly the toxic A(1-42), can be involved both directly (Butterfield & Bush, 2004) 
and indirectly (Lahiri & Greig, 2004) in the generation of ROS-RNS in the brain, thus 
causing oxidation of lipids and proteins (Qi et al., 2005) and nitration of tyrosine residues 
in proteins. As it is critical that the oxidative balance inside of the cell is tightly regulated, 
compensatory mechanisms become upregulated in normal cells that have been exposed to 
oxidant stress. These adaptive processes are found in the brain, but they can become 
dysregulated during aging (Mattson & Magnus, 2006) and in pathological states (Mattson, 
2004; Zhu et al., 2004). Mitochondria are a source of hydrogen peroxide (H2O2), and A in 
the presence of redox-active ions such as iron and copper can lead to the generation of 
excess H2O2 (Pedersen & Blusztajn, 1997). This ROS may induce cellular damage, 
particularly by the generation of highly-reactive superoxide radical anion (O2-) or 
hydroxyl radical (OH), the latter being formed in the Fenton reaction in the presence of 
redox-active iron. However, under some conditions protective mechanisms such as the 
activation of stress-activated protein kinase (SAPK) pathways are engaged with the 
induction of downstream antioxidant enzymes (Tamagno et al., 2003). Thus, A alone or 
in combination with other constituents can lead to the generation of ROS-RNS that can 
damage macromolecules and result in the modulation of neurotransmission and cause 
neurotoxicity. 
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Cholinergic presynaptic function is affected by low levels of A (pM-nM), with the result 
being decreased pyruvate dehydrogenase activity (Hoshi et al., 1996, 1997), ACh synthesis 
(Hoshi et al., 1996, 1997; Pederson et al., 1996; Pederson & Blusztajn, 1997) and release 
(Heinitz et al., 2006; Kar et al., 1996, 1998; Satoh et al., 2001). However, there are conflicting 
reports on the effects of A on the functions of both ChAT and CHT proteins. Hippocampal 
ChAT activity is decreased after several days of A administration into rat brain (Nitta et al., 
1994, 1997), but this may be due to the loss of neurons rather than to a direct effect on the 
enzyme. The acute addition of A to neural cells can either reduce ChAT activity (McMillian 
et al., 1995; Pederson et al., 1996) or have no effect (Hoshi et al., 1996, 1997; Kar et al., 1998); 
it is difficult to interpret these studies as the A conformation was not determined and it is 
increasingly clear that the oligomeric, fibrillar or other forms of A have quite different 
cellular effects. Experiments that involve the use of a variety of model systems indicate that 
the high-affinity choline uptake activity of CHT can be modulated by A, but the results are 
also variable. Some reports show that A can actually increase high-affinity choline uptake 
activity (Bales et al., 2006; Kristofikova et al., 2006), whereas others suggest that Aimpairs 
choline uptake (Apelt et al., 2002; Kar et al., 1998; Klingner et al., 2003; Kristofikova et al., 
2001, 2008; Opazo et al., 2006; Payette et al., 2007) or that Ahas no effect on high-affinity 
uptake of choline (Forgon et al., 1998; Hartmann et al., 2004; Melo et al., 2002). It is known 
that cholinergic neurochemical function is affected directly by A in a manner that is not 
related to neuron degeneration, but it is not known to what extent these effects are due to 
the oxidant stress engaged by increasing A. Unfortunately, for the most part these results 
are descriptive in nature rather than being mechanistic and do not offer insight into the 
potential reversibility of the functional changes or information that would be useful for the 
development of approaches to support cholinergic neuron function. 
5. ROS – RNS cause reversible and irreversible modification of proteins  
Reactive cysteine (Cys) thiol groups are ionized at physiological pH, and proteins having 
reactive Cys thiols are found in cells in multiple forms as they are modified by ROS and 
RNS or form homo- and hetero-protein complexes. Figure 2 shows common modifications 
that reactive Cys thiols can undergo using ChAT as the model because it is an outstanding 
example of a protein that has an unusually high number of Cys residues. The modification 
of reactive Cys thiols during oxidative or nitrosative stress is a key regulator of protein 
activity (Klatt & Lamas, 2000), and can result in either loss- or gain-of-function (Barrett et al., 
1999; Borges et al., 2002; Fukuda et al., 2005; Humphries et al., 2002; Ishii et al., 2005; Jaffrey 
et al., 2001; Lind et al., 2002; J. Wang et al., 2001). There are cellular mechanisms that protect 
proteins from irreversible inactivation by oxidation that involve the reversible addition of 
antioxidant peptides, particularly reduced glutathione (GSH) (Townsend, 2007). The 
formation of protein-GSH mixed disulphide conjugates can protect vulnerable thiol groups 
in proteins from further damage during transient oxidative stress (Borges et al., 2002; 
Jaffreyet al., 2001). A critical point is that protein-GSH mixed disulphide formation is 
reversible, with the native protein being regenerated as the interior of the cell returns to a 
more reduced state. However, the more highly oxidized forms of proteins, sulphinic (Pr-
SO2H) and sulphonic (Pr-SO3H) acids, are not reduced in cells with this leading to 
irreversible loss-of-function of the target protein. Brain and other tissues can take a double 
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hit during aging by increased ROS–RNS levels and decreased antioxidant mechanisms, with 
this characterized by a decreased ratio of reduced to oxidized GSH [GSH:GSSG]. This is 
illustrated in necropsy brain fractions from subjects that were neurologically normal or that 
had MCI or Alzheimer’s disease. The effects of oxidative stress were localized mostly to 
synaptic regions, with the largest changes seen in presynaptic [synaptosome] fractions as 
significant decreases in antioxidant levels and increases in markers of oxidative damage 
(Ansari & Scheff, 2010). These changes occurred early in the disease and the free radical 
burden increased as an active persistent process in aging and disease (Ansari & Scheff, 
2010). Similar findings are seen in aging rodents (Gilmer et al., 2010). 
 
 
Fig. 2. ROS–RNS can cause reversible and irreversible modification of proteins at reactive 
cysteine thiol residues. The common modifications that reactive Cys thiols can undergo are 
shown using ChAT as an example to illustrate that the protein can be found in cells in 
multiple forms that are modified by ROS and RNS with the potential formation of homo- 
and hetero-protein complexes. Unmodified ChAT-S- (1) is oxidized by low levels of H2O2 to 
its sulphenic acid, ChAT-S-OH (2); ChAT-S-OH reacts non-enzymatically with glutathione 
(GSH) to form ChAT-GSH mixed disulphide, ChAT-S-S-G (3) that protects Cys from further 
oxidation. ChAT-S-OH (2) is further oxidized by excess ROS to inactive sulphinic ChAT-
SO2H (4) and sulphonic ChAT-SO3H (5) acids when GSH is depleted. Also, ChAT-S- (1) can 
react with NO to form S-nitrosylated ChAT, ChAT-S-NO (6) by reaction at reactive Cys 
thiols. ChAT-S-NO (6) can also react with GSH to give ChAT-S-S-G (3). Alternatively, 
ChAT-S- (1) can be converted to ChAT-S-S-G (3) by reaction with S-nitrosoglutathione 
(GSNO). In the absence of GSH, ChAT-S- (1) can be converted by ROS to intermolecular 
dimers ChAT-S-S-ChAT  (7) or higher-order oligomers (8) that may precipitate from the 
cytoplasm. [Adapted from Giustarini et al., 2004]. 
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6. Effects of oxidative and nitrosative stress alter ChAT activity 
It is striking that ChAT contains twenty Cys residues, which is a substantially greater 
proportion of Cys (3.2%) than is normally found in intracellular proteins (~ 1%). This could 
make ChAT particularly vulnerable to oxidative-nitrosative stress. Indeed, ChAT activity is 
decreased by acute exposure of either the purified protein (Guermonprez et al., 2001; Kim et 
al., 2006; Morris, 1967; Roskoski, 1973) or brain fractions or cells (Liu et al., 1999) to ROS-
RNS agents, with some protection being given by the addition of thioreductants (Liu et al., 
1999; Morris, 1967). We found that the activity of purified human ChAT is rapidly lost in the 
absence of reducing agents and that its activity is partially recovered by the addition of fresh 
reducing agents (Kim et al., 2005). Nitric oxide (NO) donors can also inactivate ChAT with 
this effect being partially reversed by GSH (Liu et al., 1999). A common site for post-
translational modification and redox regulation of proteins is at reactive Cys thiols with this 
leading to protein S-glutathionylation or S-nitrosylation. Reactive Cys thiols (Cys-S-) are 
ionized at physiological pH and are more easily oxidized than are fully-reduced Cys (Cys-
SH). ROS-RNS could also cause both reversible and irreversible changes to ChAT resulting 
in it having altered structure and function. The functional consequences of the oxidation of 
reactive Cys thiols in ChAT could include regulation or inactivation of catalysis, homo- or 
hetero-dimerization or oligomerization by disulphide bond formation, altered binding to 
cellular protein partners, or altered protein stability. 
Structural reorganization of a protein can also serve to protect vulnerable reversibly-oxidized 
Cys residues during acute oxidative stress by the formation of intramolecular disulphide 
bonds (Cumming & Schubert, 2005). An example of this is seen in protein tyrosine 
phosphatases where a reactive catalytic Cys residue undergoes reversible oxidation to 
sulphenic acid, and then participates in the formation of an intramolecular disulphide bond 
with one of two “backdoor” Cys residues in the catalytic site to protect it from further 
oxidation to irreversible sulphinic or sulphonic acid species (Chen et al., 2009). The disulphide 
bond formed is resistant to further oxidation by low levels of ROS and can be re-reduced by 
GSH. Re-reduction of the catalytic Cys thiolate drives oxidation of the two backdoor Cys 
causing them to form a disulphide and facilitates regeneration of the active phosphatase. This 
model is significant with regard to ChAT as there are five Cys residues in its catalytic site, and 
at least four of these are arranged in a configuration that disulphide bonds may be able to form 
with only minor changes in side chain torsion angles (Kim et al., 2006). 
7. Subcellular trafficking of CHT proteins, an important mode of regulation of 
high-affinity choline uptake, is altered by nitrosative stress 
In many experimental paradigms, high-affinity choline uptake by CHT proteins is the rate-
limiting step in the production of ACh, and it is modulated by neuronal activity and 
dependent upon the sodium electrochemical gradient (Birks & MacIntosh, 1961; Guyenet et 
al., 1973; Haga, 1971; Simon & Kuhar, 1975; Yamamura & Snyder, 1972). With molecular 
tools becoming available since the cloning of the CHT gene in the year 2000 (Okuda et al., 
2000), the importance of the subcellular trafficking of CHT proteins as a regulatory 
mechanism for choline uptake, and thus for ACh production, has emerged. CHT proteins 
are distributed between the plasma membrane and subcellular compartments such as 
endosomes and synaptic vesicles (Ferguson et al., 2003; Nakata et al., 2004; Ribeiro et al., 
2003). It was discovered that CHT proteins are internalized from the plasma membrane to 
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endocytic vesicles via clathrin-mediated endocytosis (Ribeiro et al., 2003), a process that is 
dependent on a dileucine-like internalization motif located in the cytosolic carboxyl-
terminal tail of CHT (Ribeiro et al., 2005); dileucine internalization motifs interact with the 
adaptor protein 2 complex of the clathrin-mediated endocytosis machinery (Traub, 2009). A 
subsequent study showed that internalized CHT undergoes constitutive recycling to the 
plasma membrane; importantly, potassium-mediated depolarization increases the rate of 
CHT recycling in neural cells, but not in non-neural cells (Ribeiro et al., 2007b). In addition, a 
recent report indicates that preventing CHT entry into the endosomal compartment using a 
selective endosomal ablation strategy decreases both CHT levels at the cell surface and 
choline uptake activity in a time-dependent manner (Ivy et al., 2010).  
Since subcellular trafficking of CHT proteins is such a crucial mode of regulation of high-
affinity choline uptake, it is important to address the question of how oxidative/nitrosative 
stress affects the proteins involved in vesicle trafficking. It has been demonstrated by a 
number of groups that oxidative stress perturbs the dynamic endocytosis of cell surface 
proteins such as receptors and transporters, with this having key roles in regulating their 
trafficking and activity. This may involve either the modification of specific amino acids in 
cargo proteins or be related to changes in the interaction of these receptors or transporters 
with other cellular proteins involved in their trafficking. For example, the dopamine 
transporter is inactivated by the RNS peroxynitrite by an action on a Cys residue in its third 
intracellular loop, with this resulting in toxicity to dopamine neurons (Park et al., 2002). This 
is prevented, but not reversed, by GSH and some reducing agents. Other studies reveal that 
the effects of ROS-RNS agents on cell surface proteins can be mediated indirectly by an 
action on components of the protein trafficking machinery, and this can likely involve 
changes in both clathrin-mediated and clathrin-independent pathways (Ozawa et al., 2008). 
Interestingly, this does not always involve inhibition of function of the protein; NO can 
regulate endocytosis by S-nitrosylation of dynamin which then affects endocytic vesicle 
budding thus facilitating internalization of some membrane proteins (G. Wang et al., 2006). 
This gain-of-function example illustrates the physiological role for low levels of NO. It has 
also been demonstrated that peroxynitrite stimulates synaptic vesicle exocytosis and 
induces the nitration of tyrosine residues in SNARE complex proteins (Di Stasi et al., 2002). 
However, another recent report showed that the fusion of synaptic vesicles with the 
presynaptic plasma membrane is impaired by oxidative stress (Arai et al., 2011).  
Guermonprez and coworkers (2001) determined that peroxynitrite decreases CHT activity in 
synaptosomes from Torpedo marmorata. We have undertaken studies to identify the 
mechanisms by which oxidative-nitrosative stress alter choline uptake activity thereby 
interfering with cholinergic neurotransmission. Thus, we found that peroxynitrite causes a 
rapid, dose-dependent inhibition of CHT activity that is attenuated specifically by 
scavengers of peroxynitrite (Pinthong et al., 2008). Other oxidants such as H2O2 have no 
effect on CHT activity (Guermonprez et al., 2001; Pinthong et al., 2008). Importantly, doses 
of SIN-1, a peroxynitrite-generating molecule, that significantly decrease CHT activity do 
not compromise membrane integrity or alter cellular membrane potential (Pinthong et al., 
2008). The SIN-1-induced decreases in choline uptake activity correlate with decreased CHT 
cell surface levels that result from accelerated endocytosis of CHT proteins by a clathrin-
dependent mechanism (Pinthong et al., 2008).  
Based on the important role that neuronal activity has in regulating the levels of CHT that 
are available at the plasma membrane to take up choline as substrate for ACh synthesis, it is 
predicted that the reduction in synaptic efficacy that is associated with elevated oligomeric 
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A levels (Selkoe, 2002) would decrease the movement of CHT to the cell surface as 
constituents of synaptic vesicles. Thus, under conditions of oxidative-nitrosative stress, this 
effect of reduced synaptic efficacy associated with increasing oligomeric A could further 
negatively impact CHT protein levels at the plasma membrane. This in turn would lead to 
diminished cholinergic signalling, a process found to be crucial in maintaining the 
cholinergic phenotype and regulating APP metabolism (Isacson et al., 2002; Seo et al., 2001; 
Tran et al., 2002; Unger et al., 2005; Verhoeff, 2005).  
8. ROS-RNS may affect post-translational modifications and protein-protein 
interactions that regulate CHT and ChAT activities 
Post-translational modifications can greatly influence both the function and subcellular 
localization of proteins. Phosphorylation, the reversible addition of a phosphate group to 
serine, threonine or tyrosine residues, is an important signalling event that has been shown 
to regulate both ChAT and CHT proteins. The activities of both ChAT and CHT are altered 
by treatments that modulate protein kinases or change the levels of protein phosphorylation 
in the cell (Black et al., 2010; Breer & Knipper, 1990; Cancela et al., 1995; Cooke & Rylett, 
1997; Dobransky & Rylett, 2005; Ford et al., 1999; Gates et al., 2004; Guermonprez et al., 2002; 
Issa et al., 1996; Ivy et al., 2001; Knipper et al., 1992; Vogelsberg et al., 1997). Both ChAT and 
CHT proteins are phosphorylated in neural cells (Bruce & Hersh 1989; Dobransky et al., 
2000; Gates et al., 2004; Habert et al. 1992; Schmidt & Rylett 1993). ChAT is a substrate for 
protein kinase C (PKC), casein kinase 2 and calcium/calmodulin-dependent kinase II 
(Dobransky et al., 2000), and CHT activity is modulated by activation of PKC (Black et al., 
2010; Gates et al., 2004). Thus, pathological changes in protein kinase levels or functions 
could affect the functions of ChAT and/or CHT. For example, diminished PKC protein 
levels and signalling are seen in Alzheimer’s disease (Alkon et al., 2007). However, ROS can 
lead to enhanced PKC activity (Zhao et al., 2011). Since PKC plays an important role in 
regulation of both ChAT and CHT function, it will be interesting to determine how 
oxidative stress alters phosphorylation-dependent regulation of ChAT, CHT and ACh 
synthesis, and the role that this plays in the failure of cholinergic neurotransmission in 
Alzheimer’s disease and related disorders. 
Protein-protein interactions are another molecular mode of regulation of protein function 
and/or subcellular localization, and some protein binding partners for ChAT and CHT have 
now been identified (Bales et al., 2006; Dobransky et al. 2003; Ribeiro et al., 2007a; B. Wang et 
al., 2007; Xie & Guo, 2004). In general, the interaction of CHT with other cellular proteins 
regulates it subcellular distribution. Notably, it has been determined that CHT interacts with 
the carboxyl-terminus of amyloid precursor protein (APP) family members (B. Wang et al., 
2007) and with A peptide (Bales et al., 2006). Mice lacking both APP and APP-like protein 2 
have reduced levels of CHT protein at nerve terminals and this is seen as decreased high-
affinity choline uptake activity; APP appears to be a modulator of both presynaptic 
localization and endocytosis of CHT proteins (B. Wang et al., 2007). Recent data indicate that 
modulation of APP metabolism or processing is an early cellular response to oxidative stress 
(Recuero et al., 2010). Based on the intimate relationship between oxidative/nitrosative 
stress and A production, ROS-RNS generation could impact CHT activity by altering the 
interactions of this transporter with APP or A. However, the mechanisms by which 
oxidative/nitrosative stress directly affects the interactions of ChAT and CHT with their 
protein binding partners have not been investigated. 
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9. Conclusion 
The regulation of cellular proteins related to their reactions with ROS and RNS are 
described by the nitroso- and disulphide proteomes, and this has emerged as a critical 
modulator of protein function in both physiological and pathological situations (Ghezzi & 
Benetto, 2003; Lopez-Sanchez et al., 2009; Torta et al., 2008; Yano et al., 2002). A crucial point 
is that cellular mechanisms of limited capacity are normally in place, such as the formation 
of protein mixed-disulphides with glutathione (GSH), that transiently protect proteins from 
detrimental effects of ROS-RNS until redox balance is restored in the cell. S-
glutathionylation at critical reactive Cys residues may even result in a gain-of-function for 
some proteins. However, during aging and disease, GSH levels are decreased and this can 
lead to irreversible oxidation and loss-of-function of vulnerable proteins. Investigations that 
are combining a range of proteomic, cell biology and in vivo experimental approaches have 
begun to characterize the dynamic responses of cholinergic neurons to the changes in brain 
that are induced by oxidative-nitrosative stress. A critical outcome of these studies is the 
identification of conditions that determine if the structural and functional modifications to 
ChAT and CHT that occur with tissue stress have the potential to be reversible or whether 
they are persistent. Future studies should focus on defining changes that are consistent with 
healthy and successful brain aging compared to changes that are associated with the onset 
of age-related disorders such as Alzheimer’s disease. This will give insight into changes that 
are potentially reversible and that are amenable to intervention, and assist with the 
identification of therapeutic targets for protection of these proteins in normal aging and in 
diseases that may involve A-induced / oxidative stress-induced changes. 
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